Rs, Mankind
Mankind Pharma shares in focus as company approves Rs 10,000 crore fundraise plan
The company's board of directors on Monday approved raising up to Rs 5,000 crore via non-convertible debentures in 3-4 distinct series with maturities of up to 48 months, in a regulatory filing to stock exchanges.
Mankind Pharma board approves up to Rs 10,000 crore fundraising plan
The company, however, did not disclose how it aims to utilise the raised capital. In July this year, Mankind had announced the acquisition of Bharat Serums and Vaccines from Advent International for around Rs 13,
Mankind Pharma-BSV Acquisition: Rs 10,000 crore update from India’s 4th largest drug maker
In a regulatory filing to stock exchanges today, Mankind Pharma Ltd, the fourth-largest pharmaceutical company in India by market share, said that its board has approved raising up to Rs 5,000 crore through non-convertible debentures in 3-4 distinct series with maturities of upto 48 months.
Mankind Pharma board approves raising up to ₹10,000 crore via NCDs, commercial paper
Mankind Pharma has been in focus since the company announced the acquisition of Bharat Serums and Vaccines from Advent International for an enterprise value of ₹13,630 crore.
Big move by Mankind Pharma as its board decides to raise Rs 100000000000 via...
Reports indicate that Mankind Pharma plans to issue listed and rated commercial paper, with a face value to be determined as per applicable laws, for an aggregate financing amount
Mankind Pharma to Raise Rs 10,000 Crore via Debentures and Commercial Papers
Mankind Pharma plans to raise up to Rs 10,000 crore through non-convertible debentures and commercial papers. The board approved raising Rs 5,000 crore each via non-convertible debentures and commercial papers.
Mankind Pharma board approves raising of ₹10,000 cr via private placement
Mankind Pharma's Q1 profit surged 10% YoY to ₹543 crore; brokerage Motilal Oswal expects 14% earnings CAGR over FY24-26
Mankind Pharma board approves fundraising plan of up to Rs 10,000 cr
Mankind Pharma on Monday said it will raise up to Rs 10,000 crore via issuance of non-convertible debentures and commercial papers.
Mankind Pharma to Raise ₹5,000 Crore Via Non-Convertible Debentures and Commercial Papers
Mankind Pharma will issue non-convertible debentures (NCDs) and commercial papers (CP) worth ₹5,000 crore. These funds will support acquisitions and long-term growth. NCDs will be in various series, secured by company assets,
Mankind Pharma Approves Rs 10,000 Cr Fundraising
Mankind Pharma plans to raise up to Rs 10,000 crore through non-convertible debentures and commercial papers. The company will utilize the funds for growth and expansion.
Mankind Pharma to raise Rs 10,000 crore through NCDs, CPs to fund BSV deal
The company will raise up to Rs 5,000 crore through non-convertible debentures (NCDs) maturing in up to 48 months, according to a regulatory filing.
Stocks in news: TCS, Tata Power, IRCTC, Mankind Pharma, Bank of Maharashtra, SpiceJet
Mankind Pharma announced that it would raise up to Rs 10,000 crore through issuance of non-convertible debentures (NCD) and ...
The Financial Express2h
Stocks To Watch: Tata Power, Mankind Pharma, Bank of Maharashtra, NTPC, IRCTC, Unichem Labs, SpiceJet
GIFT Nifty ended 22 points or 0.08% down at 25,984.50 indicating a negative opening for domestic indices NSE Nifty 50 and BSE ...